Apellis Set For Blockbuster Success With Syfovre, The First Approved Geographic Atrophy Drug
$2,190 Per Vial Price In Line With VEGF-Based Eye Therapies
Around five million people worldwide suffer from geographic atrophy, and Apellis’s drug will be the first to offer hope of slowing the disease’s progress, as it reaches the US market at a price comparable to the VEGF inhibitors.
